L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes

Autores
Das, Undurti N.; Repossi Marquez, Pablo Gaston; Dain, Alejandro; Eynard, Aldo Renato
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications. High fat diet and carbohydrate-rich diet enhance serum asymmetrical dimethylarginine (ADMA) levels, an endogenous inhibitor of nitric oxide synthesis. ADMA levels are elevated in patients with hypertension, poor control of hyperglycemia, diabetic microangiopathy and macroangiopathy and dyslipidemia. One of the earliest signs of vascular dysfunction and insulin resistance, which are present in hypertension and type 2 diabetes mellitus, is an elevation in serum ADMA levels. Displacing plasma ADMA by oral supplementation of L-arginine restores endothelial dysfunction by augmenting endothelial nitric oxide generation. Strict control of hyperglycemia decreases serum ADMA levels. These and other studies suggest that serum ADMA levels could be used to predict the development of hypertension and type 2 diabetes mellitus in those who are at high-risk to develop these diseases.
Fil: Das, Undurti N.. UND Life Sciences; Estados Unidos
Fil: Repossi Marquez, Pablo Gaston. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; Argentina
Fil: Dain, Alejandro. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; Argentina
Fil: Eynard, Aldo Renato. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; Argentina
Materia
L-ARGININE
NITRIC OXIDE
ADMA
DIABETES
HYPERTENSION
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/281137
Acceder
id CONICETDig_d16199f025d8bb8b2893ea7eb1cec0e8
oai_identifier_str oai:ri.conicet.gov.ar:11336/281137
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetesDas, Undurti N.Repossi Marquez, Pablo GastonDain, AlejandroEynard, Aldo RenatoL-ARGININENITRIC OXIDEADMADIABETESHYPERTENSIONhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications. High fat diet and carbohydrate-rich diet enhance serum asymmetrical dimethylarginine (ADMA) levels, an endogenous inhibitor of nitric oxide synthesis. ADMA levels are elevated in patients with hypertension, poor control of hyperglycemia, diabetic microangiopathy and macroangiopathy and dyslipidemia. One of the earliest signs of vascular dysfunction and insulin resistance, which are present in hypertension and type 2 diabetes mellitus, is an elevation in serum ADMA levels. Displacing plasma ADMA by oral supplementation of L-arginine restores endothelial dysfunction by augmenting endothelial nitric oxide generation. Strict control of hyperglycemia decreases serum ADMA levels. These and other studies suggest that serum ADMA levels could be used to predict the development of hypertension and type 2 diabetes mellitus in those who are at high-risk to develop these diseases.Fil: Das, Undurti N.. UND Life Sciences; Estados UnidosFil: Repossi Marquez, Pablo Gaston. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; ArgentinaFil: Dain, Alejandro. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; ArgentinaFil: Eynard, Aldo Renato. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; ArgentinaFrontiers in Bioscience2011-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/281137Das, Undurti N.; Repossi Marquez, Pablo Gaston; Dain, Alejandro; Eynard, Aldo Renato; L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes; Frontiers in Bioscience; Frontiers in Bioscience; 16; 1; 1-2011; 13-201093-9946CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.imrpress.com/journal/FBL/16/1/10.2741/3672info:eu-repo/semantics/altIdentifier/doi/10.2741/3672info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-02-26T10:07:04Zoai:ri.conicet.gov.ar:11336/281137instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-02-26 10:07:04.279CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
title L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
spellingShingle L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
Das, Undurti N.
L-ARGININE
NITRIC OXIDE
ADMA
DIABETES
HYPERTENSION
title_short L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
title_full L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
title_fullStr L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
title_full_unstemmed L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
title_sort L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
dc.creator.none.fl_str_mv Das, Undurti N.
Repossi Marquez, Pablo Gaston
Dain, Alejandro
Eynard, Aldo Renato
author Das, Undurti N.
author_facet Das, Undurti N.
Repossi Marquez, Pablo Gaston
Dain, Alejandro
Eynard, Aldo Renato
author_role author
author2 Repossi Marquez, Pablo Gaston
Dain, Alejandro
Eynard, Aldo Renato
author2_role author
author
author
dc.subject.none.fl_str_mv L-ARGININE
NITRIC OXIDE
ADMA
DIABETES
HYPERTENSION
topic L-ARGININE
NITRIC OXIDE
ADMA
DIABETES
HYPERTENSION
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications. High fat diet and carbohydrate-rich diet enhance serum asymmetrical dimethylarginine (ADMA) levels, an endogenous inhibitor of nitric oxide synthesis. ADMA levels are elevated in patients with hypertension, poor control of hyperglycemia, diabetic microangiopathy and macroangiopathy and dyslipidemia. One of the earliest signs of vascular dysfunction and insulin resistance, which are present in hypertension and type 2 diabetes mellitus, is an elevation in serum ADMA levels. Displacing plasma ADMA by oral supplementation of L-arginine restores endothelial dysfunction by augmenting endothelial nitric oxide generation. Strict control of hyperglycemia decreases serum ADMA levels. These and other studies suggest that serum ADMA levels could be used to predict the development of hypertension and type 2 diabetes mellitus in those who are at high-risk to develop these diseases.
Fil: Das, Undurti N.. UND Life Sciences; Estados Unidos
Fil: Repossi Marquez, Pablo Gaston. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; Argentina
Fil: Dain, Alejandro. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; Argentina
Fil: Eynard, Aldo Renato. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Biología Celular; Argentina
description Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications. High fat diet and carbohydrate-rich diet enhance serum asymmetrical dimethylarginine (ADMA) levels, an endogenous inhibitor of nitric oxide synthesis. ADMA levels are elevated in patients with hypertension, poor control of hyperglycemia, diabetic microangiopathy and macroangiopathy and dyslipidemia. One of the earliest signs of vascular dysfunction and insulin resistance, which are present in hypertension and type 2 diabetes mellitus, is an elevation in serum ADMA levels. Displacing plasma ADMA by oral supplementation of L-arginine restores endothelial dysfunction by augmenting endothelial nitric oxide generation. Strict control of hyperglycemia decreases serum ADMA levels. These and other studies suggest that serum ADMA levels could be used to predict the development of hypertension and type 2 diabetes mellitus in those who are at high-risk to develop these diseases.
publishDate 2011
dc.date.none.fl_str_mv 2011-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/281137
Das, Undurti N.; Repossi Marquez, Pablo Gaston; Dain, Alejandro; Eynard, Aldo Renato; L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes; Frontiers in Bioscience; Frontiers in Bioscience; 16; 1; 1-2011; 13-20
1093-9946
CONICET Digital
CONICET
url http://hdl.handle.net/11336/281137
identifier_str_mv Das, Undurti N.; Repossi Marquez, Pablo Gaston; Dain, Alejandro; Eynard, Aldo Renato; L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes; Frontiers in Bioscience; Frontiers in Bioscience; 16; 1; 1-2011; 13-20
1093-9946
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.imrpress.com/journal/FBL/16/1/10.2741/3672
info:eu-repo/semantics/altIdentifier/doi/10.2741/3672
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers in Bioscience
publisher.none.fl_str_mv Frontiers in Bioscience
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1858305232540270592
score 13.176822

Publicaciones similares